Oral contraceptive pills are birth control pills including progestin and estrogen hormones. These hormones induce contraception/birth control by preventing ovulation. These pills are also known as combined pills or combined oral contraceptive pills (COCP). Combined oral contraceptive pills are available in five different packs: the 21-day pack, the 24-day pack, the 28-day pack, the 91-day pack and the four-phase regimen. Bayer’s Yaz and Loestrin are the most widely preferred brands of the 24-day pack. Barr Laboratories’ Seasonale and Teva Pharmaceutical Industries’ Seasonique are preferred in the 91-day pack sub-segment. In the four-phase regimen, Bayer’s Natazia dominates the market.
Oral contraceptive pills are the most common form of reversible contraception in the developed economies of the world such as the U.S., Canada, the Western Europe and Australia. Their high effectiveness (99.9% when accurately used and 92% when typically used) and convenience in use (in comparison to contraceptive devices, especially implants), drive the oral contraceptive pills segment.
This report provides in-depth analysis of the global oral contraceptives pills market. The stakeholders for this report include companies involved in the research and development, manufacturing and commercialization of oral contraceptive pills, suppliers and new entrants planning to invest in this market. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition for different oral contraceptive pills in the five major regions.
The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the oral contraceptive pills market in the current and future scenario. Further, Porter’s five forces analysis and market attractiveness analysis have been included in market overview section in order to explain the intensity of competition in the market. Porter’s five forces analysis is also elucidated in the section to understand the attractiveness of the oral contraceptive pills market in terms of the five different attributes that have an effect on the sustenance of the players in the oral contraceptive pills market. Competitive scenario among the market players is analyzed through a heat map of major market players in the competitive landscape section of the report. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.
Based on the product types, the global oral contraceptives market is segmented into combination pills, progestin only pills and others. Combination pills are further categorized into three segments including monophasic pills, triphasic pills and others. Market revenue in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 is analyzed for the various types of oral contraceptive pills.
Geographically, the oral contraceptive pills market has been differentiated into five major regions: North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). This section of the report provides with the market estimation in terms of revenue (US$ Mn) of contraceptive pills market in these five regions from 2013 to 2023. Market revenue for oral contraceptive pills is also provided for geographies along with CAGR % for period 2015 to 2023, considering 2014 as the base year.
This report also includes recommendations section that will assist new companies in establishing their presence and market players in expanding their market share in the oral contraceptive pills market. The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Actavis, Inc., Bayers AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.